Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
LMNX's Cash to Debt is ranked higher than
92% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.07 vs. LMNX: No Debt )
LMNX' s 10-Year Cash to Debt Range
Min: 3.96   Max: No Debt
Current: No Debt

Equity to Asset 0.89
LMNX's Equity to Asset is ranked higher than
94% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. LMNX: 0.89 )
LMNX' s 10-Year Equity to Asset Range
Min: 0.77   Max: 0.97
Current: 0.89

0.77
0.97
Interest Coverage 62.72
LMNX's Interest Coverage is ranked higher than
75% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.42 vs. LMNX: 62.72 )
LMNX' s 10-Year Interest Coverage Range
Min: 5.66   Max: 9999.99
Current: 62.72

5.66
9999.99
F-Score: 8
Z-Score: 15.04
M-Score: -2.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.46
LMNX's Operating margin (%) is ranked higher than
77% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. LMNX: 10.46 )
LMNX' s 10-Year Operating margin (%) Range
Min: -1523.06   Max: 12.93
Current: 10.46

-1523.06
12.93
Net-margin (%) 9.53
LMNX's Net-margin (%) is ranked higher than
82% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.64 vs. LMNX: 9.53 )
LMNX' s 10-Year Net-margin (%) Range
Min: -1449.74   Max: 14.7
Current: 9.53

-1449.74
14.7
ROE (%) 7.71
LMNX's ROE (%) is ranked higher than
75% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.15 vs. LMNX: 7.71 )
LMNX' s 10-Year ROE (%) Range
Min: -90.69   Max: 8.58
Current: 7.71

-90.69
8.58
ROA (%) 6.86
LMNX's ROA (%) is ranked higher than
82% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. LMNX: 6.86 )
LMNX' s 10-Year ROA (%) Range
Min: -82.92   Max: 7.62
Current: 6.86

-82.92
7.62
ROC (Joel Greenblatt) (%) 29.84
LMNX's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. LMNX: 29.84 )
LMNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -678.57   Max: 39.99
Current: 29.84

-678.57
39.99
Revenue Growth (3Y)(%) 15.00
LMNX's Revenue Growth (3Y)(%) is ranked higher than
90% of the 261 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. LMNX: 15.00 )
LMNX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 15   Max: 191.1
Current: 15

15
191.1
EBITDA Growth (3Y)(%) 9.90
LMNX's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 219 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. LMNX: 9.90 )
LMNX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -69.3   Max: 45.3
Current: 9.9

-69.3
45.3
EPS Growth (3Y)(%) 12.30
LMNX's EPS Growth (3Y)(%) is ranked higher than
79% of the 218 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. LMNX: 12.30 )
LMNX' s 10-Year EPS Growth (3Y)(%) Range
Min: -52.7   Max: 104.9
Current: 12.3

-52.7
104.9
» LMNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

LMNX Guru Trades in Q4 2013

Jim Simons 107,140 sh (+96.08%)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 2,475,025 sh (-2.03%)
» More
Q1 2014

LMNX Guru Trades in Q1 2014

Jim Simons 111,497 sh (+4.07%)
PRIMECAP Management 2,386,259 sh (-3.59%)
» More
Q2 2014

LMNX Guru Trades in Q2 2014

Paul Tudor Jones 25,725 sh (New)
Jim Simons 128,140 sh (+14.93%)
PRIMECAP Management 2,040,232 sh (-14.5%)
» More
Q3 2014

LMNX Guru Trades in Q3 2014

Joel Greenblatt 38,571 sh (New)
PRIMECAP Management 1,987,848 sh (-2.57%)
Paul Tudor Jones 16,667 sh (-35.21%)
Jim Simons 17,200 sh (-86.58%)
» More
» Details

Insider Trades

Latest Guru Trades with LMNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 New Buy0.01%$16.57 - $19.93 $ 18.994%38571
Joel Greenblatt 2013-12-31 Sold Out 0.03%$17.76 - $20.12 $ 18.991%0
Joel Greenblatt 2013-06-30 New Buy0.04%$15.51 - $21 $ 18.994%44843
Ron Baron 2012-09-30 Sold Out 0.15%$16.95 - $25.66 $ 18.99-2%0
PRIMECAP Management 2012-09-30 New Buy0.08%$16.95 - $25.66 $ 18.99-2%2495582
PRIMECAP Management 2012-06-30 Sold Out 0.09%$21.52 - $25.14 $ 18.99-19%0
Ron Baron 2011-09-30 Reduce -30%0.05%$18.5 - $24.62 $ 18.99-11%951610
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 38.00
LMNX's P/E(ttm) is ranked higher than
76% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.80 vs. LMNX: 38.00 )
LMNX' s 10-Year P/E(ttm) Range
Min: 29.8   Max: 646.43
Current: 38

29.8
646.43
P/B 2.69
LMNX's P/B is ranked higher than
75% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.58 vs. LMNX: 2.69 )
LMNX' s 10-Year P/B Range
Min: 2.43   Max: 12.27
Current: 2.69

2.43
12.27
P/S 3.58
LMNX's P/S is ranked higher than
67% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.76 vs. LMNX: 3.58 )
LMNX' s 10-Year P/S Range
Min: 3.14   Max: 12.99
Current: 3.58

3.14
12.99
PFCF 28.77
LMNX's PFCF is ranked higher than
85% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 55.34 vs. LMNX: 28.77 )
LMNX' s 10-Year PFCF Range
Min: 25.16   Max: 451.73
Current: 28.77

25.16
451.73
EV-to-EBIT 30.92
LMNX's EV-to-EBIT is ranked higher than
74% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.26 vs. LMNX: 30.92 )
LMNX' s 10-Year EV-to-EBIT Range
Min: -858.9   Max: 232.4
Current: 30.92

-858.9
232.4
PEG 1.54
LMNX's PEG is ranked higher than
94% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. LMNX: 1.54 )
LMNX' s 10-Year PEG Range
Min: 1.78   Max: 5.38
Current: 1.54

1.78
5.38
Shiller P/E 62.12
LMNX's Shiller P/E is ranked higher than
78% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 144.62 vs. LMNX: 62.12 )
LMNX' s 10-Year Shiller P/E Range
Min: 56.03   Max: 386.75
Current: 62.12

56.03
386.75
Current Ratio 5.77
LMNX's Current Ratio is ranked higher than
90% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.71 vs. LMNX: 5.77 )
LMNX' s 10-Year Current Ratio Range
Min: 2.39   Max: 59.71
Current: 5.77

2.39
59.71
Quick Ratio 4.59
LMNX's Quick Ratio is ranked higher than
90% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. LMNX: 4.59 )
LMNX' s 10-Year Quick Ratio Range
Min: 1.86   Max: 58.8
Current: 4.59

1.86
58.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.83
LMNX's Price/Net Cash is ranked higher than
91% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. LMNX: 14.83 )
LMNX' s 10-Year Price/Net Cash Range
Min: 3.74   Max: 135.16
Current: 14.83

3.74
135.16
Price/Net Current Asset Value 8.75
LMNX's Price/Net Current Asset Value is ranked higher than
89% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. LMNX: 8.75 )
LMNX' s 10-Year Price/Net Current Asset Value Range
Min: 3.21   Max: 116
Current: 8.75

3.21
116
Price/Tangible Book 4.22
LMNX's Price/Tangible Book is ranked higher than
75% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.73 vs. LMNX: 4.22 )
LMNX' s 10-Year Price/Tangible Book Range
Min: 2.65   Max: 16.94
Current: 4.22

2.65
16.94
Price/DCF (Projected) 1.92
LMNX's Price/DCF (Projected) is ranked higher than
81% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.67 vs. LMNX: 1.92 )
LMNX' s 10-Year Price/DCF (Projected) Range
Min: 1.77   Max: 11.52
Current: 1.92

1.77
11.52
Price/Median PS Value 0.60
LMNX's Price/Median PS Value is ranked higher than
94% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.19 vs. LMNX: 0.60 )
LMNX' s 10-Year Price/Median PS Value Range
Min: 0.56   Max: 26.57
Current: 0.6

0.56
26.57
Price/Peter Lynch Fair Value 2.25
LMNX's Price/Peter Lynch Fair Value is ranked higher than
92% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. LMNX: 2.25 )
LMNX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.3   Max: 25.89
Current: 2.25

1.3
25.89
Price/Graham Number 2.64
LMNX's Price/Graham Number is ranked higher than
84% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.76 vs. LMNX: 2.64 )
LMNX' s 10-Year Price/Graham Number Range
Min: 2.24   Max: 15.42
Current: 2.64

2.24
15.42
Earnings Yield (Greenblatt) 3.20
LMNX's Earnings Yield (Greenblatt) is ranked higher than
72% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.50 vs. LMNX: 3.20 )
LMNX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 3.7
Current: 3.2

0.4
3.7
Forward Rate of Return (Yacktman) 19.08
LMNX's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.14 vs. LMNX: 19.08 )
LMNX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -53.6   Max: 32.4
Current: 19.08

-53.6
32.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:LMX.Germany,
Luminex Corp was incorporated under the laws of the State of Texas in May 1995, and was reincorporated in the State of Delaware in July 2000. The Company develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The Company has two reportable segments; TSP segment and ARP segment. The TSP segment represents the Company's base business and consists of system sales to partners, raw bead sales, royalties, service and support of the technology, and other miscellaneous items and the ARP segment is involved in the development and sale of assays on xMAP technology for use on Luminex's installed base of systems, as well as the sale of automated punching systems. The Company also develops and manufactures the proprietary xMAP laboratory instrumentation and the proprietary xMAP microspheres and sells them. The ARP segment is mainly involved in the development and sale of assays utilizing xMAP technology on its installed base of systems. The ARP segment is mainly focused on multiplexed applications for the human molecular clinical diagnostics market. The Company's diagnostic market competitors include Abbott Laboratories, Beckman Coulter, Inc., Celera Corporation, Cepheid, Johnson & Johnson, Roche Diagnostics, Siemens Medical, and Hologic, Inc. It currently owns 281 issued patents, including 110 issued patents in the United States. The Company's trademark includes Luminex, xMAP, xTAG, Luminex 100/200 MicroPlex, MAGPIX, MagPlex, SeroMAP, xPONENT, FlexmiR, NeoPlex4, LumAvidin Et cetera. The Company is subject to federal, state and local laws and regulations relating to the protection of human health and the environment.
» More Articles for LMNX

Headlines

Articles On GuruFocus.com
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Luminex Corp. (LMNX) CEO Patrick J Balthrop buys 7,000 Shares Mar 02 2010 
Luminex Corp. (LMNX) CEO Patrick J Balthrop buys 7,000 Shares Nov 16 2009 
Luminex Corporation Reports Second Quarter 2009 Results Aug 06 2009 
Luminex Corporation Reports Fourth Quarter and Year-End 2008 Results Feb 05 2009 
Luminex Corporation Fourth Quarter and Year End 2008 Earnings Release Scheduled for February 5, 2009 Jan 21 2009 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Dec 26 2014
LUMINEX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Dec 22 2014
Bill Gross: No, I'm not crazy Dec 15 2014
Luminex Grows on Product Launches & Strategic Partnerships Dec 01 2014
LUMINEX CORP Financials Nov 04 2014
10-Q for Luminex Corp. Oct 30 2014
Luminex (LMNX) Upgraded to Strong Buy on Impressive Q3 Oct 29 2014
Mid-Day Market Update: Integrated Device Technology Jumps On Upbeat Earnings; Twitter Shares Decline Oct 28 2014
Luminex Tops Q3 Earnings, Revenues in Line; Outlook Weak Oct 28 2014
LUMINEX CORP Files SEC form 10-Q, Quarterly Report Oct 28 2014
Luminex tops 3Q revenue forecasts Oct 27 2014
Luminex tops 3Q revenue forecasts Oct 27 2014
Luminex Corp Earnings Call scheduled for 5:00 pm ET today Oct 27 2014
LUMINEX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 27 2014
Luminex Corporation Reports Third Quarter 2014 Results Oct 27 2014
Q3 2014 Luminex Corp Earnings Release - After Market Close Oct 27 2014
Luminex (LMNX) Highlighted As Strong And Under The Radar Stock Of The Day Oct 24 2014
Trading Ebola Oct 21 2014
LUMINEX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Oct 20 2014
Luminex (LMNX) Crumbles: Stock Falls by 7.5% Oct 16 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK